Relationship of Catechol-O-Methyltransferase Variants to Brain Structure and Function in a Population at High Risk of Psychosis

Biological Psychiatry

Volumn 61, Issue 10, 2007, Pages 1127-1134

  McIntosh, Andrew M ^a   Baig, Ben J ^a   Hall, Jeremy ^a   Job, Dominic ^a   Whalley, Heather C ^a   Lymer, G Katherine S ^a   Moorhead, T William J ^a   Owens, David G C ^a   Miller, Patrick ^a   Porteous, David ^a   Lawrie, Stephen M ^a   Johnstone, Eve C ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

COMT; dopamine; MRI; prefrontal; schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; VALINE;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BRAIN FUNCTION; CINGULATE GYRUS; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC RISK; GENETIC VARIABILITY; GRAY MATTER; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ALLELES; AMINO ACID SUBSTITUTION; BRAIN; CATECHOL O-METHYLTRANSFERASE; COHORT STUDIES; DOMINANCE, CEREBRAL; DOPAMINE; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GYRUS CINGULI; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC LANGUAGE; SCHIZOPHRENIC PSYCHOLOGY; SCOTLAND; VALINE;

EID: 34247576268     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.05.020     Document Type: Article

References (48)

1. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D-2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97 (2000) 8104-8109
2. Ananth H., Popescu I., Critchley H.D., Good C.D., Frackowiak R.S.J., and Dolan R.J. Cortical and subcortical grey matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am J Psychiatry 159 (2002) 1497-1505
3. Ashburner J., and Friston K.J. Voxel-based morphometry-the methods. Neuroimage 11 (2000) 1-21
4. Blasi G., Mattay V.S., Bertolino A., Elvevag B., Callicott J.H., Das S., et al. Effect of catechol-O-methyltransferase val(158)met genotype on attentional control. J Neurosci 25 (2005) 5038-5045
5. Burgess P.W., and Shallice T. Response supression, initiation and strategy use following frontal lobe lesions. Neuropsychologica 34 (1996) 263-272
6. Byrne M., Clafferty B.A., Cosway R., Grant E., Hodges A., Whalley H.C., et al. Neuropsychology, genetic liability and psychotic symptoms in those at high risk of schizophrenia. J Abnorm Psychol 112 (2003) 38-48
7. Chana G., Landau S., Beasley C., Everall I.P., and Cotter D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: Evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry 53 (2003) 1086-1098
8. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S.J., and Grasby P.M. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378 (1995) 180-182
9. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98 (2001) 6917-6922
10. Elkashef A.M., Doudet D., Bryant T., Cohen R.M., Li S.H., and Wyatt R.J. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100 (2000) 1-11
11. Fan J.B., Zhang C.S., Gu N.F., Li X.W., Sun W.W., Wang H.Y., et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis. Biol Psychiatry 57 (2005) 139-144
12. Faraone S.V., Seidman L.J., Kremen W.S., Pepple J.R., Lyons M.J., and Tsuang M.T. Neuropsychologic functioning among the non-psychotic relatives of schizophrenic patients: A diagnostic efficiency analysis. J Abnorm Psychol 104 (1995) 581-594
13. Glatt S.J., Faraone S.V., and Tsuang M.T. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: Meta-analysis of case-control and family-based studies. Am J Psychiatry 160 (2003) 469-476
14. Gothelf D., Eliez S., Thompson T., Hinard C., Penniman L., Feinstein C., et al. COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci 8 (2005) 1500-1502
15. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 10 (2005) 40-68
16. Heinrichs R.W., and Zakzanis K.K. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology 12 (1998) 426-445
17. Ho B.C., Wassink T.H., O'Leary D.S., Sheffield V.C., and Andreasen N.C. Catechol-O-methyl transferase Val(158)Met gene polymorphism in schizophrenia: Working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol Psychiatry 10 (2005) 287-298
18. Hodges A., Byrne M., Grant E., and Johnstone E. People at risk of schizophrenia. Sample characteristics of the first 100 cases in the Edinburgh High-Risk Study. Br J Psychiatry 174 (1999) 547-553
19. Jayakumar P.N., Venkatasubramanian G., Gangadhar B.N., Janakiramaiah N., and Keshavan M.S. Optimized voxel-based morphometry of gray matter volume in first-episode, antipsychotic-naIve schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 587-591
20. Job D.E., Whalley H.C., McConnell S., Glabus M., Johnstone E.C., and Lawrie S.M. Structural gray matter differences between first-episode schizophrenics and normal controls using voxel-based morphometry. Neuroimage 17 (2002) 880-889
21. Johnstone E.C., Abukmeil S.S., Byrne M., Clafferty R., Grant E., Hodges A., et al. Edinburgh high risk study-findings after four years: Demographic, attainment and psychopathological issues. Schizophr Res 46 (2000) 1-15
22. Johnstone E.C., Ebmeier K.P., Miller P., Owens D.G.C., and Lawrie S.M. Predicting schizophrenia: Findings from the Edinburgh high-risk study. Br J Psychiatry 186 (2005) 18-25
23. Karayiorgou M., and Gogos J.A. The molecular genetics of the 22q11-associated schizophrenia. Brain Res Mol Brain Res 132 (2004) 95-104
24. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., and Innis R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 46 (1999) 56-72
25. Lawrie S.M., Whalley H.C., Abukmeil S.S., Kestelman J.N., Miller P., Best J.J.K., et al. Brain structure, genetic liability and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol Psychiatry 49 (2001) 811-823
26. Lawrie S.M., Whalley H.C., Kestelman J.N., Abukmeil S.S., Byrne M., Hodges A., et al. Magnetic resonance imaging of the brain in people at high risk of developing schizophrenia. Lancet 353 (1999) 30-33
27. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34 (1995) 4202-4210
28. McDonald C., Grech A., Toulopoulou T., Schulze K., Chapple B., Sham P., et al. Brain volumes in familial and non-familial schizophrenic probands and their unaffected relatives. Am J Med Genet 114 (2002) 616-625
29. McGuffin P., Farmer A., and Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 48 (1991) 764-770
30. McIntosh A.M., Harrison L.K., Forrester K., Lawrie S.M., and Johnstone E.C. Neuropsychological impairments in patients with schizophrenia, bipolar disorder and their unaffected relatives. Br J Psychiatry 186 (2005) 378-385
31. McIntosh A.M., Job D., Moorhead T.W.J., Harrison L.K., Whalley H.C., Johnstone E.C., et al. Genetic liability to schizophrenia or bipolar disorder and its relationship to brain structure. Am J Med Genet B Neuropsychiatr Genet 141 (2006) 76-83
32. Mitchell R.L.C., Elliott R., and Woodruff P.W.R. fMRI and cognitive dysfunction in schizophrenia. Trends Cogn Sci 5 (2001) 71-81
33. Moorhead T.W., Job D.E., Spencer M.D., Whalley H.C., Johnstone E.C., and Lawrie S.M. Empirical comparison of maximal voxel and non-isotropic adjusted cluster extent results in a voxel-based morphometry study of comorbid learning disability with schizophrenia. Neuroimage 28 (2005) 544-552
34. Munafo M.R., Bowes L., Clark T.G., and Flint J. Lack of association of the COMT (Val158//108 Met) gene and schizophrenia: A meta-analysis of case-control studies. Mol Psychiatry 10 (2005) 765-770
35. Nathaniel-James D.A., Fletcher P., and Frith C.D. The functional anatomy of verbal initiation and suppression using the Hayling Test. Neuropsychologia 35 (1997) 559-566
36. Paterlini M., Zakharenko S.S., Lai W.S., Qin J., Zhang H., Mukai J., et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 8 (2005) 1586-1594
37. Seamans J.K., and Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74 (2004) 1-57
38. Seeman P. Dopamine-receptors and the dopamine hypothesis of schizophrenia. Synapse 1 (1987) 133-152
39. Seeman P., and Kapur S. Schizophrenia: More dopamine, more D-2 receptors. Proc Natl Acad Sci U S A 97 (2000) 7673-7675
40. Seidman L.J., Faraone S.V., Goldstein J.M., Kremen W.S., Horton N.J., Makris N., et al. Left hippocampal volume as a vulnerability indicator for schizophrenia-a magnetic resonance imaging morphometric study of nonpsychotic first-degree relatives. Arch Gen Psychiatry 59 (2002) 839-849
41. Shifman S., Bronstein M., Sternfeld M., Pisante-Shalom A., Lev-Lehman E., Weizman A., et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71 (2002) 1296-1302
42. Weinberger D.R., Berman K.F., and Zec R.F. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. 1. Regional cerebral blood-flow evidence. Arch Gen Psychiatry 43 (1986) 114-124
43. Whalley H.C., Kestelman J.N., Rimmington J.E., Kelso A., Abukmeil S.S., Best J.J., et al. Methodological issues in volumetric magnetic resonance imaging of the brain in the Edinburgh High Risk Project. Psychiatry Res 91 (1999) 31-44
44. Whalley H.C., Simonotto E., Flett S., Marshall I., Ebmeier K.P., Owens D.G., et al. fMRI correlates of state and trait effects in subjects at genetically enhanced risk of schizophrenia. Brain 127 (2004) 478-490
45. Williams H.J., Glaser B., Williams N.M., Norton N., Zammit S., Macgregor S., et al. No association between schizophrenia and polymorphisms in COMT in two large samples. Am J Psychiatry 162 (2005) 1736-1738
46. Wing J.K., Cooper J.E., and Sartorius N. The Description and Classification of Psychiatric Symptoms. An Instruction Manual for the PSE and Catego Systems (1974), Cambridge University Press, Cambridge, UK
47. Worsley K.J., Cao J., Paus T., Petrides M., and Evans A.C. Applications of random field theory to functional connectivity. Hum Brain Mapp 6 (1998) 364-367
48. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., and Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 157 (2000) 16-25